Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc.

1799448

Aligos Therapeutics is a clinical-stage biotechnology company headquartered in South San Francisco, California. They are focused on developing best-in-class therapies for liver and viral diseases, specifically targeting areas with high unmet medical needs. Their pipeline includes treatments for chronic HBV infection and MASH. Aligos aims to significantly improve patient outcomes through science-driven approaches and a patient-centric focus.

86
Mycket Pålitlig
Förtroendepoäng

Officiellt Register

Juridiskt Namn
Aligos Therapeutics, Inc.
Organisationsnummer
1799448
Momsnummer
000000000
Företagsstatus
Active
Adress
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA 94080
Branschkoder
Biological Products, (No Diagnostic Substances), 2836

AI Kvalitetsanalys

Bransch
Biotechnology
SSL/HTTPS
Säker
Professionell E-post
Ja
Kontakt E-post
info@aligos.com

🌟 Liknande Pålitliga Företag

Metagenomi, Inc.

Metagenomi, Inc. logo
74/100 · Pålitlig

Metagenomi is an in vivo genome editing company creating curative genetic medicines using proprietary technologies. They leverage metagenomics to discover editing tools potentially capable of correcting any type of genetic mutation. The company focuses on diseases with well-understood biology and clear regulatory pathways, and intends to expand their pipeline through genetic editing capabilities.

5959 HORTON STREET, USA
Visa profil

ARCTICZYMES TECHNOLOGIES ASA

ARCTICZYMES TECHNOLOGIES ASA logo
80/100 · Mycket Pålitlig

ArcticZymes Technologies är ett bioteknikföretag specialiserat på utveckling och produktion av enzymer. De erbjuder nukleaser för bioproduktion och molekylär diagnostik, inklusive Salt Active Nucleases (SAN). Företaget är känt för sina polymeraser och enzymer som används inom forsknings- och industriella applikationer.

Sykehusvegen 23, Norway
Visa profil

ACD PHARMACEUTICALS AS

ACD PHARMACEUTICALS AS logo
80/100 · Mycket Pålitlig

ACD Pharma is a Norwegian R&D company developing biocontrol products based on bacteriophages, focusing on combating harmful bacteria in animals and humans. They launched Custus®YRS, the world's first bacteriophage product for aquaculture. They collaborate with pharmaceutical and scientific teams to fight antibiotic resistance, extending their advancements across sectors.

Lofoten Bio Centre, Norway10 anställda
Visa profil